Statins Linked to Reduced Risk of Barrett's Esophagus

the MPR take:

In a new study published in the journal Gastroenterology, the use of statins was found to reduce the risk of Barrett's esophagus. While previous research showed that the use of these cholesterol-lowering agents reduced the risk of esophageal adenocarcinoma, little was known about how statins affected the development of Barrett's esophagus.  In the study, 303 patients with Barrett's esophagus were compared to two control groups: 606 elective endoscopy controls and 303 primary care controls without Barrett's esophagus. Statin use was ascertained via electronic pharmacy records during the 10 years before diagnosis date for Barrett's esophagus patients and study endoscopy date for controls. Compared with combined control groups, the use of statins was associated with a significantly lower risk (43%) of Barrett's esophagus, with risk being especially lower in obese patients (74%) and for long-segment Barrett's esophagus.

Background & Aims: Statins have been associated with a reduced risk of esophageal adenocarcinoma, but little is known about their effect on development of Barrett's esophagus. We evaluated the association between statins and risk of Barrett's esophagus. Methods: We conducted a case-control study among eligible patients scheduled for elective esophagogastroduodenoscopy and patients eligible for screening colonoscopy, recruited from primary care clinics at a Veterans Affairs center.